1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Sawai Cites Broader Supply Issue As It Plots Construction Of A New Facility

New Solid Dosage Form Facility Planned At Its Local Daini Kyushu Site

 
• By Dean Rudge

Japan’s Sawai was cautioned by one analyst earlier this year that it lacked sufficient excess production capacity to handle the sharp expansion in demand for its products. Now the company has announced plans to build a new solid dosage form facility.

Yellow paper boat breaks out of order from other paper boats
Sawai is looking to achieve its production goals • Source: Alamy

Japanese player Sawai Pharmaceutical Co., Ltd. has unveiled plans to build a new solid dosage form facility at its local Daini Kyushu site, citing an increase in demand for its products that has followed supply and quality issues that have plagued the Japanese generics industry this year, as well as to “strengthen production capacity in response to further market expansion of generic drugs in the future.”

“To the current annual production capacity of 2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Viatris Awaits ‘Significant Rebound’ At Indore In 2026 After Painful Q1 Bite

 
• By Dean Rudge

Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.